M
Mary Altz‐Smith
Researcher at University of Utah
Publications - 4
Citations - 486
Mary Altz‐Smith is an academic researcher from University of Utah. The author has contributed to research in topics: Auranofin & Rheumatoid arthritis. The author has an hindex of 4, co-authored 4 publications receiving 482 citations. Previous affiliations of Mary Altz‐Smith include University of Alabama at Birmingham.
Papers
More filters
Journal ArticleDOI
Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure.
Robert F. Meenan,Jennifer J. Anderson,Lewis E. Kazis,Lewis E. Kazis,Marlene J. Egger,Mary Altz‐Smith,Mary Altz‐Smith,Cecil O. Samuelson,Robert F. Willkens,Robert F. Willkens,Marilyn A. Solsky,Marilyn A. Solsky,Stanley P. Hayes,Stanley P. Hayes,Kenneth L. Blocka,Kenneth L. Blocka,Arthur Weinstein,Arthur Weinstein,Maria Guttadauria,Maria Guttadauria,Stanley B. Kaplan,Stanley B. Kaplan,John H. Klippel,John H. Klippel +23 more
TL;DR: The performance of a self-administered health status questionnaire in a randomized, double-blind, 21-week comparison of placebo, oral gold, and injectable gold in rheumatoid arthritis patients is described.
Journal ArticleDOI
Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
John R. Ward,H. James Williams,Marlene J. Egger,James C. Reading,Eric G. Boyce,Mary Altz‐Smith,Cecil O. Samuelson,Robert F. Willkens,Marilyn A. Solsky,Stanley P. Hayes,Kenneth L. Blocka,Arthur Weinstein,Robert F. Meenan,Maria Guttadauria,Stanley B. Kaplan,John H. Klippel +15 more
TL;DR: Results confirm that both parenteral and oral gold may be effective for the treatment of RA, that GST tends to show greater efficacy than auranofin, and that auran ofin has fewer significant adverse effects than GST, however, long-term benefits, tolerability, and safety cannot be inferred.
Journal ArticleDOI
Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate.
Stephen L. Dahl,Miki L. Coleman,H. James Williams,Mary Altz‐Smith,Donald R. Kay,Harold E. Paulus,Arthur Weinstein,Stanley B. Kaplan +7 more
TL;DR: Whole blood gold concentrations did not correlate with clinical outcome, as assessed by changes in joint tenderness, joint swelling, or Westergren erythrocyte sedimentation rate, and did not correlation with toxic reactions necessitating withdrawal from the study.
Journal ArticleDOI
One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo
H. James Williams,Stephen L. Dahl,John R. Ward,Miki Karg,Robert F. Willkens,Robert F. Meenan,Mary Altz‐Smith,Daniel O. Clegg,William M. Mikkelsen,Donald R. Kay,Arthur Weinstein,Maria Guttadauria,Harold E. Paulus,Stanley B. Kaplan +13 more
TL;DR: Results of this open-label study suggest that AUR has a long-term use profile similar to that of other slow-acting antirheumatic drugs and appears to be capable of sustaining an initial response to gold sodium thiomalate.